• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Janssen buys exclusive access to Evotec's insulin-producing beta cells

Janssen buys exclusive access to Evotec's insulin-producing beta cells

July 10, 2012
CenterWatch Staff

Evotec, a drug discovery alliance and development partnership company, has licensed a portfolio of small molecules and biologics designed to trigger the regeneration of insulin-producing beta cells to Janssen Pharmaceuticals.

Janssen will receive exclusive access to a series of candidates designed to trigger the beta cells. The small molecules and biologics were identified by scientists in the Harvard University laboratory of Douglas Melton, and further analyzed in collaboration with scientists from Evotec, as part of the CureBeta research and development program.

"As the funding and licensing landscape has evolved in the pharmaceutical industry, we have evolved to identify new development strategies for our research assets. This alliance with Janssen Pharmaceuticals represents an important step towards a real solution for the treatment of diabetes,” said Isaac T. Kohlberg, Harvard's chief technology development officer.

The agreement between Evotec and Janssen triggers an upfront payment of $8 million. Upon achievement of certain pre-clinical, clinical, regulatory and commercial goals, Janssen will make future milestone payments of up to $300 million per product. In addition, Janssen will pay royalties on future sales of any products that result from this collaboration. The upfront, milestone and royalty payments will be shared by Evotec and Harvard according to pre-agreed terms.

In addition, Evotec will receive research support for discovery and early development work that will be conducted in collaboration with Janssen. Janssen will also provide industrial scope and scale as well as pharmaceutical development expertise and marketing capabilities.

Upcoming Events

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing